SCHEDULE: TCG Crossover Entities Amend Fulcrum Therapeutics Filing

TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC, along with Chen Yu, have filed an amendment to their Schedule 13G for Fulcrum Therapeutics, Inc., reporting no change in beneficial ownership.

Summary

• This filing is Amendment No. 2 to a Schedule 13G for Fulcrum Therapeutics, Inc.
• The amendment is filed by TCG Crossover Fund II, L.P. (TCG Crossover II), TCG Crossover GP II, LLC (TCG Crossover GP II), and Chen Yu (the Reporting Persons).
• The filing states that as of June 30, 2026, the Reporting Persons collectively beneficially own 0.00 shares of Fulcrum Therapeutics, Inc. common stock.
• Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.
• The filing confirms that the securities were not acquired or held for the purpose of or with the effect of changing or influencing control of the issuer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily an amendment to a Schedule 13G, indicating no significant change in beneficial ownership or strategic intent from the reporting persons.

Positives

• The filing confirms that the reporting persons are not attempting to influence or change control of Fulcrum Therapeutics, Inc.

Negatives

• The reporting persons collectively beneficially own 0.00 shares of Fulcrum Therapeutics, Inc. common stock as of the filing date, indicating no significant stake.
• The filing is an amendment, suggesting a routine update rather than a new strategic development.

Risks

• No specific risks are detailed in this Schedule 13G amendment, as it primarily serves to update ownership information.

Future Outlook

No forward-looking statements or guidance are provided in this Schedule 13G amendment.

Management Comments

• Each Reporting Person disclaims beneficial ownership of all securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. Amendments indicate changes in holdings or are routine updates. The zero ownership reported here suggests a divestment or a correction of previous filings.

Comparison to Industry Standards

• Schedule 13G filings are standard for institutional investors exceeding 5% ownership. The zero ownership reported by TCG Crossover entities is unusual if they were previously significant holders, suggesting a complete exit or a reporting error that is now corrected.

Stakeholder Impact

• Shareholders may note the absence of a significant stake from TCG Crossover entities, which could influence market perception if they were previously considered a major investor.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Schedule 13G, Fulcrum Therapeutics, TCG Crossover Fund II, TCG Crossover GP II, Chen Yu, Beneficial Ownership, Amendment